Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (1219)	12/14/1998 11:32:00 PM
From: poodle	Read Replies (1) \| Respond to of 1510

Jake, thanks a lot for informative post. I was informed about AGPH/IMNR merger rumors long time ago. Seriously doubt it may happen. We will see Wed evening.

To: jake burns who wrote (1219)	12/21/1998 8:34:00 AM
From: Emec	Respond to of 1510

Picked up by Dow Jones Immune Response Corp. Dow Jones Newswires -- December 21, 1998 Immune Response Arthritis Treatment Safe, Well-Tolerated CARLSBAD, Calif. (Dow Jones)--Immune Response Corp.'s (IMNR) Phase IIb clinical trial for the treatment of rheumatoid arthritis suggested a "favorable" treatment effect that was safe and well-tolerated, the company said. In a press release Monday, Immune Response said the five-arm, double-blind, placebo-controlled clinical trial with 340 patients was designed to evaluate the company's potential T-cell receptor peptide therapeutic vaccine in an effort to select the best dose and formulation for future clinical development. The results suggest a favorable treatment effect according to the American College of Rheumatology criteria for improvement, with statistical significance at one time point after the third injection, and were consistent with and expanded upon the results shown in the previous Phase II trial. Immune Response plans to continue discussions to select a corporate partner to further develop this product. Immune Response is a biopharmaceutical company.